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Abstract 
 
Objective 
FURIN is a proprotein convertase enzyme that inhibits the pro-inflammatory function of T 
cells and myeloid cells. Previously, elevated FURIN expression levels have been reported in 
immune-mediated diseases, such as primary Sjögren’s syndrome.  Here, we investigated the 
levels of FURIN in peripheral blood (PB) and synovial fluid (SF) leukocytes from patients 
with rheumatoid arthritis (RA).  
Methods 
FURIN mRNA expression in PB and SF cells was determined by qRT-PCR and FURIN 
plasma levels were measured using ELISA. Associations between FURIN levels and 
demographic and clinical characteristics of the patients were determined. 
Results 
FURIN levels were significantly elevated in PB and SF mononuclear cells, T cells and 
monocytes from RA patients when compared to healthy controls. High FURIN levels were 
significantly associated with the prevailing prednisolone treatment, higher prednisolone doses 
as well as increased CRP levels and Health Assessment Questionnaire (HAQ) values. 
Conclusion 
FURIN is significantly upregulated in RA PB and SF leukocytes, suggesting that FURIN 
may have a role in the pathogenesis of RA. In addition, our results suggest that elevated 
FURIN expression is associated with the indicators of more severe RA.  
 
Keywords: RA, FURIN, proprotein convertase, biomarker, T cell, monocyte 
 
 
  
Introduction 
 
In RA, T cells, B cells, macrophages and dendritic cells accumulate into the joints. Different 
cell types promote inflammation by secreting pro-inflammatory cytokines, such as TNF-α, 
IFN-γ, GM-CSF, IL-1, IL-6 and IL-17 [1]. These events ultimately lead to chronic 
inflammation, synovial hyperplasia and degradation of articular cartilage and bone [2].   
FURIN is the first discovered mammalian proprotein convertase (PCSK) enzyme. FURIN 
belongs to the subtilisin superfamily of serine endoproteases and it converts immature pro-
proteins into functional units [3]. FURIN is essential for mammalian development and tissue 
homeostasis, but it also contributes to the pathogenesis of several diseases including cancers, 
elevated blood pressure and atherosclerosis [4][5][6].   
FURIN is important in the regulation of the immune system. Deleting FURIN in mouse T 
cells results in a loss of peripheral immune tolerance and aberrant T helper cell polarization 
[7]. In the myeloid cells FURIN inhibits inflammatory responses by reducing the production 
of pro-inflammatory cytokines [8]. The function of FURIN in immunoregulation is not 
entirely clear, but its expression in immune cells is critical for the functional maturation of 
anti-inflammatory pro-TGF-β1 cytokine and the suppressive function of regulatory T cells 
[7]. 
Preliminary evidence also suggests that FURIN plays a role in the pathogenesis of human 
autoimmune diseases. In primary Sjögren’s syndrome, an upregulated expression of FURIN 
has been detected in salivary gland biopsies [9], and in peripheral circulation [10]. 
Previously, we found an association between high plasma level of FURIN and a history of 
rheumatic disease in a prospective cohort study of patients with a suspected infection in the 
emergency room [11]. We have therefore investigated FURIN levels in peripheral blood (PB) 
and synovial fluid (SF) leukocytes from RA patients. We also explored possible associations 
between FURIN levels and demographic and clinical characteristics of the patients.  
 
 
  
Patients and methods 
 
Patient samples 
PB and SF samples were collected from patients with active RA. The characteristics of the 
patient cohorts are presented in Tables 1 and 2. In addition, purified T cells and monocytes 
were obtained from eight RA patients: median (range) age 62 (37-87) years, duration of 
disease 18.5 (0.25-49) years, CRP 25 (18-67.4) g/L and ESR 35.5 (10-91) mm/h. Control 
samples were obtained from healthy blood donors (Finnish Red Cross Blood Transfusion 
Service, Tampere). 
All patients gave their written informed consent. This study was approved by the Ethical 
Committee of Tampere University Hospital, Tampere, Finland, and conducted according to 
the principles of the Declaration of Helsinki. 
Cell preparations 
PB mononuclear cells (PBMCs) and SF mononuclear cells (SFMCs) were isolated by Ficoll-
Paque Plus (Amersham Biosciences, Buckinghamshire, UK) density gradient centrifugation. 
T cells and monocytes were further purified from eight RA patients using magnetic beads 
(Miltenyi Biotec, Auburn, CA, USA). T cells were purified by negative selection (Pan T Cell 
Isolation Kit; Miltenyi Biotec) and monocytes were isolated by positive selection using anti-
CD14-coated microbeads. 
RNA isolation and quantitative RT-PCR analysis 
Total RNA was isolated using the RNeasy MiniKit (Qiagen, Valencia, CA, USA). Total 
RNA was reverse transcribed using Maxima Reverse Transcriptase (Thermo Scientific, 
Waltham, MA, USA) and random hexamers (Thermo Scientific). The real-time PCR were 
done with the CFX96 instrument (Bio-Rad, Hercules, CA, USA) using Maxima SYBR 
Green/ROX master mix (Thermo Scientific). 
The following primers for FURIN and TATA-binding protein (TBP, housekeeping) were 
used: 5′-GAATATAATCCCAAGCGGTTTG-3′ and 5′-ACTTCACATCACAGCTCCCC-3' 
for TBP and 5’-GGCAAAGCGACGGACTAAAC-3’ and 5’-
CGTCCAGAATGGAGACCACA-3’ for FURIN. 
Mean FURIN expression values from triplicate samples were obtained by dividing them by 
the mean values obtained for the TBP housekeeping gene. 
FURIN ELISA 
FURIN plasma levels were measured using the Human Furin ELISA kit (Thermo Scientific). 
Duplicate determinations were carried out for each sample. The analysis was performed with 
a cut-off by dividing samples into those that were below detection threshold (< 123 pg/ml) 
and above it (≥ 123 pg/ml) 
Statistical analysis 
Statistical analyses were performed using SPSS Statistics (IBM, version 22). Fisher´s Exact 
Test was used to test the relationship between two binomial variables. Analyses including 
ordinal and scale variables were conducted using Mann-Whitney U-Test (Exact). The 
correlations for continuous variables were calculated using Spearman´s correlation 
coefficient.  
  
 
  
Results 
 
Increased expression of FURIN in PB and SF T cells and monocytes from RA patients 
First, we examined the levels of FURIN mRNA in PBMCs from patients with active RA and 
healthy controls. The expression of FURIN was significantly elevated in PBMCs from RA 
patients when compared with healthy controls (Figure 1A; p<0.001).  
To gain better insight into the cell population which express the increased levels of FURIN, 
we studied the expression of FURIN mRNA in isolated PB T cells and monocytes. As shown 
in Figure 1B and 1C, the levels of FURIN were elevated in both PB T cells and monocytes 
from RA patients when compared to healthy controls, with monocytes expressing higher 
levels of FURIN than T cells. 
In RA, synovial T cells and macrophages are exposed to various inflammatory stimuli, and 
show activated phenotype compared to the cells in PB. To investigate whether the cells from 
the inflamed joints express even higher levels of FURIN, SFMC, SF T cells and SF 
monocytes were isolated from patients with active RA presenting with arthritis of the knee 
joint. The levels of FURIN mRNA in SFMCs, T cells and monocytes were comparable to 
those in RA PB cells (Figure 1A-C). 
Finally, we also evaluated FURIN plasma levels in patients with RA and healthy controls. 
Plasma FURIN levels in both healthy controls and patients with RA varied considerably and 
no significant difference was observed between RA patients and healthy controls (Figure 1D; 
p=0.23). However, more patients (10 out of 17, 59%) than controls (5 out of 14, 35%) 
demonstrated detectable levels of FURIN (> 123 pg/ml).  
 
Correlation of FURIN levels with clinical characteristics of RA patients 
We next examined whether FURIN mRNA levels in PBMC or SFMC correlated with any of 
the demographic or clinical characteristics of RA patients. We found a significant correlation 
between current prednisolone use (p=0.020) and dose (p=0.004) and FURIN mRNA levels in 
PBMC. The expression of FURIN in SFMC, in turn, showed very strong correlation to the 
CRP level (Table 1; p<0.001). In addition, there were trends towards associations between 
FURIN level in SFMC and ESR level (r=0.6667, p=0.0710) and prednisolone dose 
(r=0.6747, p=0.0664). 
We also examined whether FURIN levels in plasma associated with any of the clinical 
characteristics. HAQ disability index (p=0.003) and prednisolone dose (p=0.023) were 
significantly higher in the group demonstrating detectable levels of FURIN (Table 2). In 
addition, IL-1β, IL-2, IL-4, IL-6, IL-7, IL-10, IFN-γ and TNF-α levels in plasma were 
determined in ten patients and their levels were correlated to those of FURIN. The median 
levels of all cytokines studied were higher in the group demonstrating detectable levels of 
FURIN (n=7) compared to patients presenting with undetectable FURIN levels (n=3; data not 
shown). However, this difference was significant only in the case of IL-2 (median 28 pg/ml 
versus 6 pg/ml, p=0.033). 
 
 
 
  
Discussion 
 
The expression of FURIN in RA has not been systematically studied earlier, and no data are 
available regarding FURIN expression in leukocytes from RA patients. Lin et al [12] reported 
upregulated expression of FURIN in synovial pannus derived from three patients with RA. In 
addition to RA, FURIN has been found to be upregulated in PBMCs and salivary gland 
biopsies in primary Sjögren’s syndrome [9][10]. Elevated FURIN levels have also been seen 
in patients with systemic lupus erythematosus (SLE) [13]. Together, these previous results 
and our current findings showing increased FURIN expression in RA indicate that FURIN is 
upregulated in different types of rheumatic diseases. 
Our results show that FURIN levels associate with prednisolone treatment and dose, CRP and 
ESR levels and HAQ disability index. Since prednisolone is used in the treatment of active 
RA, these findings suggest that FURIN is elevated mostly in patients with active and severe 
disease. This conclusion is supported by the fact that patients with elevated FURIN levels 
showed also global upregulation of plasma cytokines, particularly T-cell-activation-
associated IL-2. These findings are also in line with our previous results indicating that 
FURIN expression is upregulated upon the activation of T cells and macrophages [5][7]. 
However, the inflammatory response in RA joints per se does not seem to result in further 
FURIN upregulation, since comparable levels of FURIN were observed in PB and SF 
samples. 
Previous results suggest that FURIN has chiefly a protective role in arthritis. Systemic 
administration of FURIN was shown to ameliorate collagen-induced arthritis in mice [12]. In 
addition, inhibition of FURIN was shown to enhance the invasive phenotype of synoviocytes 
from patients with RA [14]. The protective role of FURIN in autoimmunity is also supported 
by previous results showing that FURIN is essential in maintaining peripheral immune 
tolerance [7] and it inhibits proinflammatory cytokine production in myeloid cells [8]. 
Notably, FURIN has also been reported to inhibit matrix metalloproteinase 13 and to limit 
osteoarthritis in mice [15]. The idea of using FURIN, its biologically active derivatives or its 
inhibitors in the treatment inflammatory diseases has been documented in patent applications 
(US20040127396A1, WO2011144517A1). 
Our current results suggesting that FURIN expression associates with more active and severe 
RA, are in line with previous data showing the upregulation of anti-inflammatory cytokines 
IL-10 and TGF-β [1] in RA patients. The overexpression of these regulatory proteins may 
reflect an attempt to combat inflammation, but due to the plethora of pro-inflammatory 
mediators present in RA, inflammation persists despite the actions of FURIN and other 
immunosuppressive proteins.  
Taken together, our data demonstrate that FURIN is upregulated in severe RA. Further 
investigations are warranted to better determine the role of FURIN in the pathogenesis of RA 
and its potential value as a biomarker in inflammatory diseases. 
 
 
Acknowledgments 
We thank Paula Kosonen, Merja Lehtinen and Heidi Peussa for technical assistance. 
Funding 
This work was supported by the Academy of Finland (Grants 295814 and 286477), the 
Competitive State Research Financing of the Expert Responsibility area of Tampere 
University Hospital (Grants 9U047, 9V049 and 9M120), the Tampere Tuberculosis 
Foundation, the Sigrid Juselius Foundation, Jane and Aatos Erkko Foundation, the Finnish 
Cultural Foundation Pirkanmaa Regional fund and the Cancer Society of Finland. 
Conflicts of interest 
The authors declare that they have no conflicts of interest. 
 
References 
 
1.  McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis - shaping the 
immunological landscape. Nat. Rev. Rheumatol. 2016;12:63–8. 
2.  Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 
2017;46:183–96. 
3.  Turpeinen H, Ortutay Z, Pesu M. Genetics of the first seven proprotein convertase 
enzymes in health and disease. Curr. Genomics. 2013;14:453–67. 
4.  Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and 
disease. Nat. Rev. Mol. Cell Biol. 2002;3:753–66. 
5.  Turpeinen H, Raitoharju E, Oksanen A, Oksala N, Levula M, Lyytikainen L-P et al. 
Proprotein convertases in human atherosclerotic plaques: the overexpression of 
FURIN and its substrate cytokines BAFF and APRIL. Atherosclerosis. 2011;219:799–
806. 
6.  Turpeinen H, Seppala I, Lyytikainen L-P, Raitoharju E, Hutri-Kahonen N, Levula M et 
al. A genome-wide expression quantitative trait loci analysis of proprotein convertase 
subtilisin/kexin enzymes identifies a novel regulatory gene variant for FURIN 
expression and blood pressure. Hum. Genet. 2015;134:627–36. 
7.  Pesu M, Watford WT, Wei L, Xu L, Fuss I, Strober W et al. T-cell-expressed 
proprotein convertase furin is essential for maintenance of peripheral immune 
tolerance. Nature. 2008;455:246–50. 
8.  Cordova ZM, Gronholm A, Kytola V, Taverniti V, Hamalainen S, Aittomaki S et al. 
Myeloid cell expressed proprotein convertase FURIN attenuates inflammation. 
Oncotarget. 2016;7:54392–404. 
9.  Sisto M, Lisi S, Lofrumento DD, Ingravallo G, Mitolo V, D’Amore M. Expression of 
pro-inflammatory TACE-TNF-alpha-amphiregulin axis in Sjogren’s syndrome salivary 
glands. Histochem. Cell Biol. 2010;134:345–53. 
10.  Ranta N, Valli A, Gronholm A, Silvennoinen O, Isomaki P, Pesu M et al. Proprotein 
convertase enzyme FURIN is upregulated in primary Sjogren’s syndrome. Clin. Exp. 
Rheumatol. 2018. 
11.  Ranta N, Turpeinen H, Oksanen A, Hamalainen S, Huttunen R, Uusitalo-Seppala R et 
al. The Plasma Level of Proprotein Convertase FURIN in Patients with Suspected 
Infection in the Emergency Room: A Prospective Cohort Study. Scand. J. Immunol. 
2015;82:539–46. 
12.  Lin H, Ah Kioon M-D, Lalou C, Larghero J, Launay J-M, Khatib A-M et al. Protective 
role of systemic furin in immune response-induced arthritis. Arthritis Rheum. 
2012;64:2878–86. 
13.  Wu T, Ding H, Han J, Arriens C, Wei C, Han W et al. Antibody-Array-Based 
Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A 
Discovery Study. J. Proteome Res. 2016;15:2102–14. 
14.  Wu C, Song Z, Liu H, Pan J, Jiang H, Liu C. Inhibition of furin results in increased 
growth , invasiveness and cytokine production of synoviocytes from patients with 
rheumatoid arthritis. Jt. Bone Spine. 2017;84:433–9. 
15.  Lin H, Hay E, Latourte A, Funck-Brentano T, Bouaziz W, Ea H-K et al. Proprotein 
convertase furin inhibits matrix metalloproteinase 13 in a TGFβ-dependent manner 
and limits osteoarthritis in mice. 2018:1–9. 
 
Table 1. The associations of patients’ characteristics and clinical parameters with FURIN mRNA levels in PBMC and SFMC. 
                         FURIN mRNA in PBMC      FURIN mRNA in SFMC 
    N = 16   r  p-value   N = 8   r  p-value 
Characteristic 
Agea (years)   66 (32 - 88)  0.0074  0.9784   54 (32 – 72)  – 0.0238 0.9554 
Gender (male)   7 (44 %)    0.7577   6 (75 %)    0.8571 
Duration of disease (years) 15 (0 - 37)  - 0.0517 0.8493   11 (1 - 37)  – 0.4762 0.2329 
 
Clinical parameters           
CRPb, g/l   30 (11 - 114)  0.3944  0.1306   44 (15 - 114)  0.9523  0.0003 
ESRc, mm/h   42 (10 - 118)  0.0383  0.8881   32 (10 - 88)  0.6667  0.0710 
Number of swollen joints 7 (1 - 16)  0.3208  0.2258   7 (1 - 9)  0.3879  0.3423 
Number of tender joints  6 (0 - 16)  0.2316  0.3880   3 (1 - 9)  – 0.1473 0.7278 
DAS28d (ESR)   5.3 (3.0 - 6.3)  0.2235  0.4053   4.8 (3.0 - 5.6)  0.4192  0.3013 
VASe, global health  56 (0 - 100)  0.4341  0.0929   47 (1 - 90)  0.5714  0.1390 
VAS, pain   58 (0 - 100)  0.3765  0.1506   47 (2 - 92)  0.5714  0.1390 
HAQf    1.51 (0.00 - 2.50) 0.1550  0.5666   1.19 (0.00 - 1.74) – 0.2892 0.4873 
Rheumatoid factor positivity 10 (63 %)    0.1471   3 (38 %)    0.1429 
 
Current treatment        
Prednisolon   12 (75 %)    0.0198   6 (75 %)     0.4286 
Prednisolon dose (mg)  6.3 (0.0 - 15.0)  0.6809  0.0037   8.8 (0.0 - 25.0)  0.6747  0.0664 
Methotrexate   7 (44 %)    0.6065   4 (50 %)     0.3429 
DMARDg   15 (94 %)    0.2500   7 (88 %)    1.0000 
Biologics   2 (13 %)    0.2667   4 (50 %)     0.8857 
The data are reported as median (and range) or number (and percentage). 
The expression of FURIN mRNA was calculated in relation to the TBP expression (FURIN/TBP) 
aAge at the time of sampling. 
bC-reactive protein. 
cErythrocyte sedimentation rate. 
dDisease Activity Score. 
eVisual Analogue Scale. 
fHealth Assessment Questionnaire. 
gDisease-modifying antirheumatic drug. 
  
Table 2. Patients’ characteristics and clinical parameters in all plasma samples and in two groups showing FURIN plasma levels below or above the detection 
threshold of FURIN ELISA. 
 
    All samples (N=17)  FURIN < 123 pg/ml (N=7)  FURIN ≥ 123 pg/ml (N = 10)  p-value 
Characteristic     
Agea (years)   66 (52 - 88)   66 (58 - 77)    68 (52 - 88)    0.9056 
Gender (male)   4 (24 %)   1 (14 %)    3 (30 %)    0.6029 
Duration of disease (years) 7 (0 - 29)   7 (0 - 26)    8.5 (0 - 29)    0.9619 
     
Clinical parameters     
CRPb, g/l   18 (0 - 68)   16 (0 - 39)    20 (0 - 68)    0.3772 
ESRc, mm/h   40 (7 - 118)   40 (7 - 80)    41 (8 - 118)    0.5843 
Number of swollen joints 8 (1 - 15)   7 (1 - 9)    8 (4 - 15)    0.1633 
Number of tender joints  6 (0 - 37)   6 (3 - 25)    5.5 (0 - 37)    0.9423 
DAS28d (ESR)   5.6 (3.5 - 6.9)   5.5 (3.7 - 5.9)    5.7 (3.5 - 6.9)    0.2698 
VASe, global health  63 (0 - 93)   56 (0 - 85)    72 (5 - 93)    0.3638 
VAS, pain   55 (0 -100)   54 (0 - 88)    64 (6 - 100)    0.5537 
HAQf    1.25 (0.63 - 2.75)  0.75 (0.63 - 1.63)   1.74 (0.75 - 2.75)   0.0031 
Rheumatoid factor positivity 10 (59 %)   3 (43 %)    7 (70 %)    0.3500 
     
Current treatment     
Prednisolon   13 (77 %)   4 (57 %)    9 (90 %)    0.2500 
Prednisolon dose (mg)  7.5 (0.0 - 27.5)   5 (0.0 - 7.5)    10 (0.0 - 27.5)    0.0234 
Methotrexate   8 (47 %)   3 (43 %)    5 (50 %)    1.0000 
DMARDg   12 (71%)   5 (71 %)    7 (70 %)    1.0000 
Biologics   4 (24 %)   1 (14 %)    3 (30 %)    0.6029 
The data are reported as median (and range) or number (and percentage). 
P-values were derived from comparisons of the groups showing FURIN levels below or above the detection threshold of FURIN ELISA 
aAge at the time of sampling. 
bC-reactive protein. 
cErythrocyte sedimentation rate. 
dDisease Activity Score. 
eVisual Analogue Scale. 
fHealth Assessment Questionnaire. 
gDisease-modifying antirheumatic drug. 
 Figure legends  
Fig 1: FURIN mRNA expression (A-C) and FURIN plasma levels (D) in patients with RA 
and healthy controls. 
Levels of FURIN mRNA were analyzed by qRT-PCR in PB mononuclear cells (n=16) and 
SF mononuclear cells (n=8; A), T cells (n=7 for PB and 4 for SF; B) and monocytes (n=6 for 
PB and 4 for SF; C) from healthy controls and patients with RA. Paired PB/SF samples were 
available from three patients in the mononuclear cell analysis, from four patients in the T cell 
analysis and from three patients in the monocyte analysis. The data are presented as relative 
FURIN expression divided by TBP level (A-C). FURIN protein levels were measured by 
ELISA in plasma samples from healthy controls and RA patients (D). Horizontal lines 
indicate the mean expression levels in each group. The detection limit of the assay was 123 
pg/ml. Significant differences between study groups are marked with an asterisk: *p<0.05, 
**p<0.01, ***p<0.001. RA: rheumatoid arthritis; PB: peripheral blood; SF: synovial fluid; 
TBP: TATA-binding protein.  
